Fig. 13. Effect of pre-treatment of WM266-4 cells with caspase inibitors on levels of LC3-II and lamin A/C cleavage in the presence of 2155-14. (A) Representative western blot of lamin A/C in the presence of 10 µM caspase inibitors. (B) Representative western blot of LC3 in the presence of 10 µM caspase inibitors. (C) Quantification of western blot of cleaved lamin A/C in the presence of 10 µM caspase inibitors. (D) Quantification of western blot of LC3-II in the presence of 10 µM caspase inibitors. (E) Representative western blot of lamin A/C in the presence of 50 µM caspase inibitors. (F) Representative western blot of LC3 in the presence of 50 µM caspase inibitors. (G) Quantification of western blot of cleaved lamin A/C in the presence of 50 µM caspase inibitors. (H) Quantification of western blot of LC3-II in the presence of 50 µM caspase inibitors. One-way analysis of variance (ANOVA) was used followed by Dunnett post hoc test. The data shown were the mean ± SD, n=3. ***** - p<0.0001, *** - p<0.001, ** - p<0.01, * - p<0.05, ns - no significance. 2155-14 was tested at 100 µM. Rap/CHQ = Rapamycin (5 µM)/Chloroquine (10 µM). Caspase 2 inh = Z-VDVAD-FMK, Caspase 6 inh = Z-VEID-FMK, Caspase 8 inh = Z-IETD-FMK, pan-Caspase inh = Z-VAD-FMK.